The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals has announced topline results from its LUGANO trial, the first of two pivotal Phase 3 studies evaluating DURAVYU for the treatment of wet age-related macular degeneration (AMD).
The LUGANO trial is a key step in the companys late-stage development program and could lead to a new treatment option for patients if subsequent results are positive. Detailed results and further information are available via the companys official communication.
View post on X Loading...
Eyepoint previously reported Phase 3 enrollment completion for DURAVYU in diabetic macular edema trials, with topline data expected in late 2027, according to a recent update. The company’s most recent financial results and corporate strategy were outlined in its Q2 2026 report. These developments reflect Eyepoint’s ongoing efforts to advance DURAVYU across multiple indications.